B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

A Phase II, Randomized, Double-Blind, Vehicle Controlled Study of the Efficacy, Safety, and Tolerability of B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis

This is a double-blind, randomized, vehicle-controlled study to assess the efficacy, safety, and tolerability of 2 doses of B244 for the treatment of pruritus in adults with a history of atopic dermatitis. Subjects who meet the study entry criteria will be randomized in a 1:1:1 ratio to receive twice daily topical doses of B244 O.D. 5.0, B244 O.D. 20.0, or vehicle (placebo) for 4 weeks.

Study Overview

• Status: Completed
• Conditions: Atopic Dermatitis
• Intervention / Treatment: Biological: B244; Biological: Vehicle

Detailed Description

This is a Prospective, Vehicle Controlled, Double-Blind, Multicenter, Randomized Phase II Trial, comparing the effect of twice daily B244 applications for 4 weeks vs vehicle applications on treatment of mild to moderate pruritus associated with atopic dermatitis.

• Approximately 576 subjects may be enrolled.
• The total duration of the study will be approximately 11 weeks. Participants will report for a Screening visit and if all inclusion/exclusion criteria are met, subjects will go through a two-week washout phase before reporting for a Baseline visit.
• After screening and baseline, participants will be randomized to one of two doses of B244 or vehicle application for 4 weeks.
• Randomization will be 1:1:1 so that an equal number of patients will be treated in each Arm of the study.
• All B244 randomized subjects will be treated at the dose of O.D. 5.0 or O.D. 20.0
• Subjects must be willing and able to complete diary within a consistent time frame on a daily basis and to comply with restrictions on allowable therapies for the duration of the study.
• All subjects will attend a screening visit not more than 21 days prior to Baseline (Day 0).
• Subjects will be required to return to the clinic at Baseline, Day 14 (Week 2) and Day 28 (Week 4) visits. All subjects will be asked to attend a Week 8 follow-up visit 4 weeks (28 (±3) days) after the last dose of study medication.
• Subjects will apply a total of 10 pumps of IP per application across all affected areas twice-a-day (i.e. 10 pumps in the morning and 10 pumps again at night) for 4 weeks.
• Safety evaluations will consist of review of participant's medical history at screening and on-going assessment of adverse events reported throughout the study duration.

• Study Type: Interventional
• Enrollment (Actual): 547
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35244
      • Cahaba Dermatology
  • Arizona
    • Phoenix, Arizona, United States, 85018
      • Elite Clinical Studies, LLC
    • Scottsdale, Arizona, United States, 85260
      • Cognitive Clinical Trials
  • Arkansas
    • Bryant, Arkansas, United States, 72022
      • Dermatology Trial Associates
    • Little Rock, Arkansas, United States, 72212
      • Applied Research Center of Arkansas, Inc
  • California
    • Cerritos, California, United States, 90703
      • Core Healthcare Group
    • Encino, California, United States, 91436
      • Encino Research Center
    • Fremont, California, United States, 94538
      • Center for Dermatology, INC
    • Lancaster, California, United States, 93534
      • Antelope Valley Clinical Trials
    • Long Beach, California, United States, 90806
      • Long Beach Clinical Trials Services
    • Los Angeles, California, United States, 90057
      • L.A. Universal Research Center Inc
    • North Hollywood, California, United States, 91606
      • Providence Clinical Research
    • Santa Ana, California, United States, 92705
      • Syrentis Clinical Research
  • Colorado
    • Centennial, Colorado, United States, 80112
      • IMMUNOe Research Centers
  • Florida
    • Clearwater, Florida, United States, 33761
      • Tampa Bay Medical Research
    • Miami, Florida, United States, 33136
      • South Coast Research Center, Inc
    • Miami, Florida, United States, 33155
      • D&H National Research Center
    • Miami Gardens, Florida, United States, 33014
      • Meridian International Research
    • Pompano Beach, Florida, United States, 33064
      • Napa Research
    • Tampa, Florida, United States, 33607
      • Clinical Research Trials of Florida, Inc
    • Tampa, Florida, United States, 33609
      • Moore Clinical Research
  • Illinois
    • Normal, Illinois, United States, 61761
      • Sneeze Wheeze & Itch Associates, LLC
  • Kansas
    • Overland Park, Kansas, United States, 66215
      • Epiphany Dermatology
  • Louisiana
    • Baton Rouge, Louisiana, United States, 70808
      • Meridian Clinical Research
  • Maryland
    • Towson, Maryland, United States, 21204
      • Continental Clinical Solutions
  • Michigan
    • Auburn Hills, Michigan, United States, 48326
      • Oakland Hills Dermatology
    • Clarkston, Michigan, United States, 48346
      • Clarkston Dermatology
    • Flint, Michigan, United States, 48507
      • Onyx Clinical Reserach
  • Missouri
    • Saint Joseph, Missouri, United States, 64506
      • Medisearch Clinical Trials
  • Nevada
    • Las Vegas, Nevada, United States, 89148
      • JDR Dermatology Research, LLC
  • New Hampshire
    • Portsmouth, New Hampshire, United States, 03801
      • ActivMed Practices & Research
  • New Jersey
    • Verona, New Jersey, United States, 07044
      • The Dermatology Group, P. C.
  • New York
    • Brooklyn, New York, United States, 11230
      • Drug Trials Brooklyn
    • Hartsdale, New York, United States, 10530
      • Drug Trials America
    • New York, New York, United States, 10075
      • Saddick Research Group
  • North Carolina
    • High Point, North Carolina, United States, 27262
      • Dermatology Consulting Services, LLC
    • Raleigh, North Carolina, United States, 27612
      • Wake Research
  • Ohio
    • Cleveland, Ohio, United States, 44130
      • Clinical Research Solutions
  • Oklahoma
    • Oklahoma City, Oklahoma, United States, 73118
      • Unity Clinical Research
  • Oregon
    • Medford, Oregon, United States, 97504
      • Crisor LLC C/O Clinical Research Institute of Southern Oregon, Inc
  • Pennsylvania
    • Sugarloaf, Pennsylvania, United States, 18249
      • Dermdox Centers for Dematology
    • Upper Saint Clair, Pennsylvania, United States, 15241
      • Peak Research LLC
  • Rhode Island
    • Cranston, Rhode Island, United States, 02920
      • Greater Providence Clinical Research
    • Warwick, Rhode Island, United States, 02886
      • Omega Medical Research
    • Warwick, Rhode Island, United States, 02886
      • AAPRI Research
  • South Carolina
    • Charleston, South Carolina, United States, 29407
      • Dermatology & Laser Center of Charleston
  • Tennessee
    • Milan, Tennessee, United States, 38358
      • Clinical Research Solutions
  • Texas
    • Plano, Texas, United States, 75024
      • ACRC Trials
  • Utah
    • Orem, Utah, United States, 84058
      • Aspen Dermatology
    • Salt Lake City, Utah, United States, 84117
      • Advance Clinical Research
  • Virginia
    • Richmond, Virginia, United States, 23219
      • Dominion Medical Associates

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male and female subjects 18 to 65 years of age.

2. Pruritus of at least 4 weeks duration prior to the initial Screening visit and during the 2 week washout period.

   a. Subjects using stable doses of oral H1 antihistamines at the initial Screening visit must be willing to continue these at the same doses and frequencies throughout the study inclusive of the follow-up period.

3. Worst Itch Numeric Rating Scale (WI-NRS) score ≥ 7 in the 24-hour period prior to the initial Screening as well as Baseline visits.
4. Average weekly WI-NRS score ≥6 for each week of the washout period, as recorded in the eDiary.

5. A history of atopic dermatitis for greater than 12 months consistent with a diagnosis of atopic dermatitis, as defined by the 2014 American Academy of Dermatology (AAD) Guidelines of Care for the Management of Atopic Dermatitis.

   1. Subjects using bland emollients at the initial Screening visit will be allowed to continue to use their emollient of choice at the same dose and frequency throughout the study.
   2. Subjects using low- to mid-potency topical corticosteroids at the initial Screening visit will be allowed to use their topical corticosteroid of choice at the same dose and frequency no more than 7 days per month throughout the study as rescue medication.

6. A minimum of 10% and not more than 40% of the subjects' BSA affected by atopic dermatitis (affected is defined by physical examination findings: erythema, edema, scaling, lichenification, excoriation, with the excoriation serving as the physical examination correlate of pruritus) at Screening and Baseline.

   a. Subjects' BSA can include face and body OR body alone BUT NOT face alone.

7. An Investigator Global Assessment (IGA) score of 2-3 at Screening and Baseline.
8. Willing and able to complete once-daily eDiary entries within a consistent timeframe for the duration of the study and have ≥80% eDiary compliance rate during the washout period.
9. Judged to be in good health in the investigator's opinion.,

Exclusion Criteria:

1. Clearly defined etiology for pruritus other than atopic dermatitis. These include but are not limited to urticaria, psoriasis or other non-atopic dermatologic conditions, hepatic or renal disease, psychogenic pruritus, drug reaction, untreated hyperthyroidism, parasite presence and presence of acute infection either systemically or in the AD lesions.
2. Presence of any acute condition which may risk inducing an atopic dermatitis flare during the course of the study, such as impetigo or active herpes simplex infection.
3. Treatment with systemic corticosteroids within 4 weeks prior to randomization.
4. Treatment with Class III or higher potency topical corticosteroids or any topical anti-pruritic therapies (other than stable doses of low- or mid-potency topical corticosteroids or bland emollients) within 4 weeks prior to randomization.

5. Treatment with systemic therapies with recognized anti-pruritic (e.g. tricyclic antidepressants, sedatives, tranquilizers, gabapentin, marijuana or other cannabinoids, opioid receptor agonists/antagonists) or pruritic (e.g. opioids, angiotensin-converting enzyme inhibitors, cocaine,,antimalarials) properties within 4 weeks prior to randomization.

   a. Stable doses of H1 antihistamines will be permitted. Subjects must be willing to continue these at the same doses and frequencies throughout the study inclusive of the follow-up period.

6. Any clinically significant changes in type, dose, or frequency of bland emollients, low- or mid-potency corticosteroids, and/or oral H1 antihistamines throughout the study from screening to follow-up.
7. Treatment with systemic immunosuppressive/ immunomodulatory therapies within 4 weeks prior to randomization (including but not limited to phosphodiesterase-4 inhibitors, cyclosporine, mycophenolate-mofetil, methotrexate, azathioprine, interferon-gamma, or phototherapy).
8. Treatment with biologic therapies within 12 weeks or 5 half-lives prior to randomization, whichever is longer.
9. Use of an indoor tanning facility within 4 weeks prior to randomization.
10. Treatment with any investigational therapy within 4 weeks prior to randomization.
11. Allergen immunotherapy within 6 months prior to randomization.
12. Prior use of AO+ Mist.
13. History of malignancy within 5 years prior to randomization, with the exception of completely treated and non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin.
14. History of a major psychiatric condition (including major depressive disorder, bipolar disorder, or schizophrenia), suicidal ideation, or suicide attempt.
15. Known active hepatitis infection.
16. Known history of human immunodeficiency virus (HIV) infection.
17. Presence of any medical condition or disability that, in the investigator's opinion, could interfere with the assessment of safety or efficacy in this trial or compromise the safety of the subject.
18. Currently pregnant or breastfeeding, or male subject with a pregnant or breastfeeding partner.
19. Females of childbearing potential who are unable or unwilling to practice highly effective contraception (pregnancy prevention); fertile males who are unable or unwilling to use condoms with female partners of childbearing potential.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: B244 Suspension O.D. 5.0; One arm of 192 Subjects will be receiving a dose of B244 O.D. 5.0 suspension	Biological: B244; B244 suspension
Experimental: B244 Suspension O.D. 20.0; Second arm of 192 subjects will receive a dose of B244 O.D. 20.0 suspension	Biological: B244; B244 suspension
Placebo Comparator: Placebo; Third arm of 192 subjects will receive a vehicle dosing.	Biological: Vehicle; Vehicle suspension

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean change in WI-NRS from baseline to Week 4	Assessing the efficacy of B244 by measuring the mean change in WI-NRS reported by subjects from baseline to Week 4	4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)	Assessing the safety and tolerability of B244 by monitoring the incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)	11 weeks

Collaborators and Investigators

• Sponsor: AOBiome LLC
• Collaborators: bioRASI, LLC
• Investigators: Study Director: Hyun Kim, PhD, AOBiome LLC

Study record dates

Study Major Dates

• Study Start (Actual): June 4, 2020
• Primary Completion (Actual): December 10, 2021
• Study Completion (Actual): January 7, 2022

Study Registration Dates

• First Submitted: July 16, 2020
• First Submitted That Met QC Criteria: July 24, 2020
• First Posted (Actual): July 28, 2020

Study Record Updates

• Last Update Posted (Actual): October 14, 2022
• Last Update Submitted That Met QC Criteria: October 7, 2022
• Last Verified: October 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Immune System Diseases; Hypersensitivity, Immediate; Genetic Diseases, Inborn; Skin Diseases, Genetic; Hypersensitivity; Skin Manifestations; Skin Diseases, Eczematous; Dermatitis; Eczema; Pruritus; Dermatitis, Atopic
• Other Study ID Numbers: PRB244-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No